UTICAJ FAKTORA RIZIKA NA EFIKASNOST MEDIKAMENTOZNE TERAPIJE KOD BOLESNIKA SA FUNKCIONALNOM ISHEMIJOM DONJIH EKSTREMITETA
Sažetak
Analiza uticaja faktora rizika na medikamentoznu terapiju, merena produženjem klaudikacione distance, kod bolesnika sa funkcionalnom ishemijom donjih ekstremiteta (FIDE) može značajno unaprediti individualni pristup u njihovom lečenju.
Cilj rada bio je da se utvrdi uticaj faktora rizika na efikasnost medikamentozne terapije kod bolesnika sa FIDE.
Istraživanjem su obuhvaćena 82 bolesnika sa dijagnostikovanom FIDE (Fontaine IIa, IIb) lečena na Klinici za vaskularnu hirurgiju Univerzitetskog kliničkog centra u Nišu u periodu od januara do 31. decembra 2020. godine.
Nakon šest meseci pregleda, uočena je statistički značajna razlika u produženju klaudikacione distance u odnosu na terapijski modalitet kod žena (p = 0,03), bolesnika sa dislipidemijom (p = 0,001) i bolesnika sa hipertenzijom (p = 0,02), uz napomenu da je veća efikasnost postignuta u grupi ispitanika koji su koristili cilostazol i acetilsalicilnu kiselinu (ASK).
Faktori rizika koji umnogome utiču na primenjeni terapijski modalitet jesu pripadnost ženskom polu, dislipidemija i hipertenzija; uzrast, gojaznost i pripadnost muškom polu faktori su rizika kod kojih navedena korelacija nije prisutna. Terapija cilostazolom i ASK-om bila je efikasnija od terapije pentoksifilinom i ASK-om u grupi ispitanika sa hipertenzijom i dislipidemijom, kao i kod žena.
Reference
Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients, editor. BMJ 2002; 324(7329): 71–86. [CrossRef] [PubMed]
Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg 2019; 58(1S): S1-S109.e33 [CrossRef] [PubMed]
Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109(7): 523-30. [CrossRef] [PubMed]
de Silvaa A, Sampatha W, Sameeraa N, Amarasinghea Y, Mitanib A..Development of a novel telecare system, integrated with plantar pressure measurement system. Informatics in Medicine Unlocked 2018, 12: 98–105. [CrossRef]
Fontaine R, Kim M, Kieny R. Surgical treatment of peripheral circulation disorders. Helv Chir Acta 1954; 21(5–6): 499–533. [PubMed]
Gallagher KA, Meltzer AJ, Ravin RA, Graham A, Connolly P, Escobar G, et al. Gender differences in outcomes of endovascular treatment of infrainguinal peripheral artery disease. Vasc Endovascular Surg 2011; 45(8): 703-11. [CrossRef] [PubMed]
Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 2017; 135(12): e686–e725. [CrossRef] [PubMed]
Guest JF, Davie AM, Clegg JP. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. Curr Med Res Opin 2005; 21(6): 817-26. [CrossRef] [PubMed]
Gupta K, Mahakalkar C, Kaple M, Deshpande S, Ladhha P, Jain N. A comparative study of cilostazol and pentoxifylline in intermittent claudication in peripheral arterial disease. J Datta Meghe Inst Med Sci Univ 2017; 12: 11-6. [CrossRef]
Guralnik JM, Balfour JL, Volpato S. The ratio of older women to men: historical perspectives and cross-national comparisons. Aging (Milano) 2000; 12(2): 65-76. [CrossRef] [PubMed]
Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286(11): 1317–24. [CrossRef] [PubMed]
Kim NH, Kim HY, An H, Seo JA, Kim NH, Choi KM, et al. Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial. Diabetol Metab Syndr 2013; 5(1): 41. [CrossRef] [PubMed]
Melfi R, Ricottini E. Antiplatelet therapy for peripheral artery disease. Cardiovasc Diagn Ther 2018; 8(5): 663-77. [CrossRef] [PubMed]
Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143(6): 961-5. [CrossRef] [PubMed]
Pachi, A, Ji, Tianjian. Frequency and velocity of people walking. The Structural Engineer 2005; 83: 36-40.
Pande R L, Hiatt W R, Zhang P, Hittel N, Creager M A. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med 2010; 15(03): 181–8. [CrossRef] [PubMed]
Peach G, Griffin M, Jones KG, Thompson MM, Hinchliffe RJ. Diagnosis and management of peripheral arterial disease. BMJ 2012; 345: e5208. [CrossRef] [PubMed]
Rao KM, Simel DL, Cohen HJ, Crawford J, Currie MS. Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication. J Lab Clin Med 1990; 115(6): 738–44. [PubMed]
Real J, Serna MC, Giner-Soriano M, Forés R, Pera G, Ribes E, et al. Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database. BMC Cardiovasc Disord 2018; 18(1): 85. [CrossRef] [PubMed]
Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001; 35(1): 48-56. [CrossRef] [PubMed]
Rizzo M, Corrado E, Patti AM, Rini GB, Mikhailidis DP. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother 2011; 12(4): 647-55. [CrossRef] [PubMed]
Saati A, AlHajri N, Ya'qoub L, Ahmed W, Alasnag M. Peripheral Vascular Disease in Women: Therapeutic Options in 2019. Curr Treat Options Cardiovasc Med 2019; 21(11): 68. [CrossRef] [PubMed]
Schramm K, Rochon PJ. Gender Differences in Peripheral Vascular Disease. Semin Intervent Radiol 2018; 35(1): 9-16. [CrossRef] [PubMed]
Singh S, Armstrong EJ, Sherif W, Alvandi B, Westin GG, Singh GD, et al. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty. Vasc Med 2014; 19(4): 307–14. [CrossRef] [PubMed]
Singh S, Singh H, Kohli A, Kapoor V, Singh G. Effects of cilostazole and pentoxifylline on claudication distance and lipid profile in patients with occlusive peripheral arterial disease: A comparative trial. IJTCVS 2009; 25: 45–8. [CrossRef]
Thiruvoipati T, Kielhorn CE, Armstrong EJ. Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World J Diabetes 2015; 6(7): 961–9. [CrossRef] [PubMed]
Thompson GR, Partridge J. Coronary calcification score: the coronary-risk impact factor. Lancet 2004; 363(9408): 557-9. [CrossRef] [PubMed]
Tsigkou V, Siasos G, Rovos K, Tripyla N, Tousoulis D. Peripheral artery disease and antiplatelet treatment. Curr Opin Pharmacol 2018; 39: 43-52. [CrossRef] [PubMed]
